HIV

ART alone cannot eradicate HIV because of the persistence of viral reservoirs, and plasma viremia promptly rebounds shortly after discontinuation of ART.

The study shows that tenofovir diphosphate concentrations in dried blood spots predict future viremia in persons living with HIV, even if virologically-suppressed, and suggest its possible use as a complement to HIV viral load to monitor the efficacy of antiretroviral therapy

Increases in cocaine injecting and homelessness have created a ‘perfect storm’ for transmission of HIV, the authors say.

The authors assessed the prevalence and clinical outcomes of poor immune response in children on suppressive antiretroviral therapy within the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)

A large study, conducted in Guinea-Bissau, shows immunological differences between HIV-2 and HIV-1 infection in addition to those described in previous studies, that may help to explain the slower disease progression in HIV-2 infected patients

40% of London allocation, and a third of national places, have still not been accepted

Authors show that severely lymphopenic HIV-infected patients with reduced thymic function have persistently low CD4+ T cell counts during antiretroviral therapy and propose predictive models to their identification

New injectables raise the possibility of once-monthly antiretroviral treatment

A study, conducted in HIV-positive patients enrolled in TAHOD, shows that age-associated comorbidities do not affect virologic outcomes of cART and older patients with comorbidities are more likely to experience immunological failure compared to those aged <50 years

New adviser is Dr Michael Brady of the Terrence Higgins Trust and King’s College Hospital.

Worldwide, approximately 1000 persons with HIV die from tuberculosis each day. Only a small proportion of those eligible to receive isoniazid are actually treated.

A patient experienced HIV-1 remission following allogeneic haematopoietic stem-cell transplantation (allo-HSCT) procedures using a donor with a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32/Δ32).

Each week of delay made early suppression less likely.

New option could be safer than F/TDF formulation.